Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
3 Months Ended 116 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Condensed Consolidated Statements Of Operations      
Revenues         
Operating expenses:      
Amortization & depreciation 194 194 77,320
General and administrative 138,626 233,641 13,490,423
Total operating expenses 138,820 233,835 13,567,743
Gain (loss) from operations (138,820) (233,835) (13,567,743)
Other income (expense):      
Loss on fair value adjustment - derivatives (10,051) (95,613) (271,986)
Gain on debt reversal    5,571 99,805
Gain on sale of fixed asset       4,790
Interest expense (41,854) (40,400) (1,305,274)
Interest expense - beneficial conversion feature (10,664) (77,103) 286,889
Total other income (expense) (62,569) (207,545) (1,759,554)
Loss before provision for income taxes (201,389) (441,380) (15,327,297)
Provision for income tax         
Net loss (201,389) (441,380) (15,327,297)
Less: Net loss attributable to noncontrolling interest (1,194) (2,905) (94,442)
Net loss attributable to TranBioTec, Inc. $ (200,195) $ (438,475) $ (15,232,855)
Net loss per share      
(Basic and fully diluted) $ (0.01) $ (0.01)  
Weighted average number of common shares outstanding 35,007,823 31,164,488